Specialty enzymes market has recently added a report Forecast to 2030 to its repository, which comprises data relating to the market size, share, value, and volume, production processes, revenue generation, the regional analysis of the business vertical, along with the outcomes of analytical tools including, SWOT analysis and Porter’s Five Forces analysis. The report highlights the growth opportunities and challenges that industry players might encounter in the forecast years, along with an elaborate competitive landscape and expansion strategies adopted by the companies functioning in the Market.
The rise in demand for non-harmful biological catalysts in pharmaceuticals & advanced tools to optimize pharmaceutical production are some of the key factors driving market revenue growth
Specialty Enzymes Market Size – USD 4,565 Million in 2021, Market Growth – at a CAGR of 7.0%, Market Trends – Increasing R&D funding for pharma and biotech companies
The rising prevalence of diseases associated with metabolism has been witnessed in recent years wherein an appropriate understanding of enzyme abnormality has led to the increasing use of enzymes as disease markers in clinical examinations. Enzymes’ selectivity for specific tissues or organs aids in identifying the site of damage, which helps in disease diagnosis. Changing levels of Lactate Dehydrogenase (LDH) in the blood is a preferred approach adopted for detecting the onset of cardiovascular diseases; this enzyme is specifically found in the heart and skeletal muscle in two distinguished forms.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Specialty enzymes are employed in various diagnostic applications such as DNA manipulation and sequencing. The decline in the cost of DNA manipulation and sequencing is projected to drive demand and increase the usage of enzymes in research & biotechnology and pharmaceuticals applications. An increase in the geriatric population in developed countries is also anticipated to boost demand for healthcare specialty enzymes.
Microorganisms segment revenue is expected to expand at a substantially rapid CAGR during the forecast period. The main benefit of microbial enzyme production is that it produces large yields on low-cost media in a shorter amount of time. Microbial enzymes are a valuable resource for medicinal treatments as they are economical, consistent, and easy to isolate.
The polymerases & nucleases segment is expected to register a significantly robust revenue growth rate over the forecast period due to the increased use of polymerases and nucleases enzymes in advanced biotechnology applications such as DNA amplification and DNA sequencing
North America is expected to register a considerably steady revenue growth rate in the global specialty enzymes market over the forecast period due to technological advancements in this region which makes enzymes available for a wide range of applications
Major companies in the market report include Novozymes, Kerry, Inc., Chr. Hansen Holding A/S, Dupont De Nemours, Inc., Associated British Foods Plc, Specialty Enzymes & Probiotics., AST Enzymes, Sanofi, Amano Enzyme, Amgen Inc., Roche Holding, Codexis, Dyadic International, Thermo Fisher Scientific, Biocatalysts, and Merck KGaA
In November 2021, Novozymes and Novo Nordisk Pharmatech announced a collaboration agreement that combined the companies’ joint competencies and interests in the development of specialty enzymes for use in biopharma processing and regenerative medicines.
Source: EIN News
